The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sat., Nov. 1, 3:59 AM

Slide #3. Chimerix, Inc. Secondary Offering

Company: Chimerix, Inc. (NASDAQ:CMRX)
Date announced: 10/29/2014
Shares Offered: 3,650,000
Date of Pricing: 10/30/2014
Price Per Share: $29
Secondary Offering Details: Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that it intends to offer and sell, subject to market and other conditions, approximately $105,000,000 of its common stock in an underwritten public offering. In connection with this offering, Chimerix expects to grant the underwriters a 30-day option to purchase up to approximately $15,750,000 of additional shares of its common stock. Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC are acting as joint book-running managers for the offering, and Cowen and Company, LLC, Piper Jaffray & Co. and Stifel, Nicolaus & Company, Incorporated are acting as co-lead managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the size or terms of the offering. Chimerix anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital. - updated 10/31 - Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the pricing of an underwritten public offering of 3,650,000 shares of its common stock at a price to the public of $29 per share. The gross proceeds to Chimerix from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Chimerix, are expected to be approximately $105.9 million. The offering is expected to close on or about November 5, 2014, subject to customary closing conditions. Chimerix anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.

Chimerix is a biopharmaceutical company engaged in the discovery, development and commercializing of oral antivirals to address unmet medical needs. Co. has two nucleotide compounds in clinical development that utilize its proprietary lipid technology. Co.'s lead compound, brincidofovir (CMX001), is in Phase 3 clinical development; its second compound, CMX157, was licensed to Merck Sharp & Dohme Corp. after completing a Phase 1 study. In addition, Co. has an active discovery program utilizing its lipid technology and the Chimerix Chemical Library, both focusing on viral targets in areas of unmet medical need.
Open the CMRX Page at The Online Investor »

Company Name:  Chimerix Inc.
Website:  www.chimerix.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding CMRX:  17
Total Market Value Held by ETFs:  $53.69M
Total Market Capitalization:  $1.06B
% of Market Cap. Held by ETFs:  5.05%
 

Open the CMRX Page at The Online Investor (in a new window) »

November 1, 2014    3:59 AM Eastern
Quotes delayed 20 minutes



Strong Buy (3.92 out of 4)
85th percentile
(ranked higher than approx. 85% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.